Literature DB >> 16020890

Successful treatment of progressive Henoch-Schönlein purpura nephritis with tonsillectomy and steroid pulse therapy.

Hitoshi Sugiyama1, Naomi Watanabe, Tetsuya Onoda, Yoko Kikumoto, Miki Yamamoto, Manabu Maeta, Nobuya Ohara, Yohei Maeshima, Yasushi Yamasaki, Hirofumi Makino.   

Abstract

Henoch-Schönlein purpura (HSP) is a systemic disorder characterized by a leukocytoclastic vasculitis involving small vessels with the deposition of IgA immune complexes. The renal involvement is the major cause of morbidity and mortality in patients with HSP. We report here an adult patient with HSP nephritis (HSPN) accompanied by persistent proteinuria and progressive renal dysfunction despite conventional therapy. The patient was successfully treated with tonsillectomy followed by intravenous pulse methylprednisolone and oral prednisone. The combination therapy resulted in a significant decrease in proteinuria, improvement of renal function and the disappearance of microhematuria. The patient finally reached a stage of clinical remission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020890     DOI: 10.2169/internalmedicine.44.611

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  Clinical remission of Henoch-Schönlein purpura nephritis after a monotherapeutic tonsillectomy.

Authors:  Yoshitaka Iwazu; Tetsu Akimoto; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-09-09       Impact factor: 2.801

2.  An adult case of severe steroid-resistant Henoch-Schönlein purpura nephritis treated with intravenous cyclophosphamide and tonsillectomy.

Authors:  Emi Sasaki; Maki Shibata; Asami Kato; Naoto Hamano; Takashi Katsuki; Manami Tada; Fumihiko Hinoshita
Journal:  CEN Case Rep       Date:  2016-07-13

3.  Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.

Authors:  Shinichiro Ohara; Yukihiko Kawasaki; Hiromi Matsuura; Tomoko Oikawa; Kazuhide Suyama; Mitsuaki Hosoya
Journal:  Clin Exp Nephrol       Date:  2011-05-28       Impact factor: 2.801

4.  Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil.

Authors:  Yue Du; Ling Hou; Chengguang Zhao; Mei Han; Yubin Wu
Journal:  Pediatr Nephrol       Date:  2011-11-13       Impact factor: 3.714

Review 5.  The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis.

Authors:  Yukihiko Kawasaki
Journal:  Clin Exp Nephrol       Date:  2011-06-23       Impact factor: 2.801

6.  Recurrence and graft loss after renal transplantation in adults with IgA vasculitis.

Authors:  Mayuko Kawabe; Izumi Yamamoto; Yo Komatsuzaki; Takafumi Yamakawa; Haruki Katsumata; Ai Katsuma; Aki Mafune; Yasuyuki Nakada; Akimitsu Kobayashi; Yudo Tanno; Ichiro Ohkido; Nobuo Tsuboi; Keitaro Yokoyama; Shigeru Horita; Masayoshi Okumi; Hideki Ishida; Hiroyasu Yamamoto; Takashi Yokoo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2016-09-27       Impact factor: 2.801

7.  Early treatment with methylprednisolone pulse therapy combined with tonsillectomy for heavy proteinuric henoch-schönlein purpura nephritis in children.

Authors:  Hiroaki Kanai; Emi Sawanobori; Anna Kobayashi; Kyoko Matsushita; Kanji Sugita; Kosuke Higashida
Journal:  Nephron Extra       Date:  2011-10-14

8.  Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient.

Authors:  Hiroaki Kanai; Anna Kobayashi; Kyoko Matsushita; Emi Sawanobori; Kanji Sugita; Kosuke Higashida
Journal:  CEN Case Rep       Date:  2013-01-12

9.  Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hiroyuki Komatsu; Shouichi Fujimoto; Shoichi Maruyama; Masashi Mukoyama; Hitoshi Sugiyama; Kazuhiko Tsuruya; Hiroshi Sato; Jun Soma; Junko Yano; Seiji Itano; Tomoya Nishino; Toshinobu Sato; Ichiei Narita; Hitoshi Yokoyama
Journal:  PLoS One       Date:  2018-05-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.